1 / 43

European Studies– Ovarian Cancer

European Studies– Ovarian Cancer. Definition Primary/Acquired Histopathology Heterogeneity Trials Future Directions. 100. 90. 80. 70. Overall Logrank test: p=0.001. 60. 50. 40. 30. 20. 10. 0. (years). 0. 1. 2. 3. 4. 5. 6. 7. 8. O. N. Number of patients at risk :.

trula
Télécharger la présentation

European Studies– Ovarian Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. European Studies– Ovarian Cancer Definition Primary/Acquired Histopathology Heterogeneity Trials Future Directions

  2. 100 90 80 70 Overall Logrank test: p=0.001 60 50 40 30 20 10 0 (years) 0 1 2 3 4 5 6 7 8 O N Number of patients at risk : 268 338 266 179 127 91 74 54 9 CP 243 342 292 221 167 126 105 76 6 TP Overall Survival Update with 6.5 years median follow-up B. Baron, March 2002

  3. Dose dense chemotherapy Carboplatin AUC6 +weekly paclitaxel 80 mg/m2/week Katsumata et al Lancet 2009

  4. Overall Survival ICON and EORTC combined (n = 925) HR = 0.68, p=0.01 95%CI (0.51, 0.92) Absolute difference At 5 year=8% (74% 82%) 95%CI (2%, 11%)

  5. Carboplatin vs Carbo/paclitaxel – Early ovarian cancer Adams et al BJOG 2010

  6. What Is Ovarian Cancer? Picture clipping

  7. 100 80 60 40 20 0 0 – 6 7 – 12 13 – 18 > 18 Interval from previous treatment, mo Relationship of Treatment-Free Interval & Response to Therapy • Independent Predictors of Response (Eisenhauer) • Serous Histology p=0.009 • No. of Disease Sites (<3) p=0.003 • Tumour size (<5cm) p=0.001 • Time since last chemo p=0.008 • <6 vs>6 months Response rate, % Blackledge et al.Br J Cancer 1989; 59: 650-653

  8. 1000 100 Survival Response • 957 ( days ) rate (%) 800 80 Overall survival • • 600 60 60 • Response • 393 rate • 400 40 • • • • • • 217 33 339 • • • • 200 20 • • - Progression • 174 9 free survival • • 90 0 0 0 - 3 /Pr 0 - 3 3 - 6 6 - 9 9 - 12 12 - 18 >18 GINECO. ASCO 2002 TFI ( months ) Treatment-Free Interval and Efficacy

  9. Breast Cancer Subtyping Her2 +ve Luminal A Luminal B Triple negative/ Basal Normal like

  10. % of mutation frequency ND ND Kuo et al 2009

  11. PersonalisedMedicine Molecular signature 1-90 genes/ER/kras/ b-raf /ECM Surrogate marker CA125 PET imaging Platinum sensitive BRCAmut or - like

  12. Relative survival – ovarian cancer subtypen=8704 7RCTs Mackay et al 2010

  13. Mucinous vs Serous Ovar 3, ICON5 and GOG182 had central path review

  14. PPM1D amplification in OCCA Tumours • PPM1D Amplified in 10% of OCCA tumours • Potential therapeutic target in a subset of OCCAs with wt p53 Tan et al CCR 2009

  15. Tp53 and Drug Resistance Shang Oncogene 2010

  16. Lee et al 2007 J Pathol

  17. BRCA1/2 alterations and outcome Henessey et al JCO 2010

  18. Genetic Alterations - EOC

  19. Bowtell D 2010

  20. Tothill et al 2008

  21. Selection of Targeted Therapy _ Ovarian Cancer

  22. Mucinous Ovarian Cancer (MeOC) • Carboplatin+paclitaxel x 6 cycles • vs Oxaliplatin 150mg/m2+capcitabine 1000mg/m2 Chemotherapy and 2 X 2 with bevacizumab

  23. OVAR 16/LUPTS Carboplatin AUC6 Primary endpoint: OS Secondary endpoint: PFS Arm A Paclitaxel 175 mg/m2 Placebo? Sub-optimally debulked Stage III/ IV OC Carboplatin AUC6 Arm B Paclitaxel 175 mg/m2 1:1:1 Randomization BBIF 1120 Stratification variables: PS (0-1 vs 2), stage (III vs IV) 15 months* Cycles (q3wk)* * Taxane consolidation therapy prohibited

  24. OVAR pazopanib Carboplatin AUC6 Primary endpoint: OS Secondary endpoint: PFS Arm A Paclitaxel 175 mg/m2 Placebo? Stage I/II OC Carboplatin AUC6 Arm B Paclitaxel 175 mg/m2 2:1 Randomization Pazopanib Stratification variables: PS (0-1 vs 2), stage (III vs IV) 15 months* Cycles (q3wk)* * Taxane consolidation therapy prohibited

  25. Summary and Future Directions • Greater understanding of molecular basis of ovarian cancers • Heterogeneity • intertumoural and intratumoural • Histopathology • Immunochemistry • stroma • mutation/CNA • Matching drugs to targets • systems biology • multidisciplinary working • education/training • EUTROC - www.eutroc.org

  26. Bowtell D 2010

  27. PARP phase 2 trials

  28. Mechanism of PARPi

  29. BRCAness Hennessy et al 2010

  30. Merlo et al.Nature Reviews Cancer advance online publication; published online 16 November 2006 | doi:10.1038/nrc2013

  31. Cisplatin + Paclitaxel IV vs IPOverall Survival Armstrong et al. NEJM 2006; 354 (1): 34-43

  32. Weekly ( dose dense) paclitaxel Patients were randomly assigned to receive carboplatin to an AUC 6 with either paclitaxel at 180 mg/m2 on day 1 or paclitaxel at 80 mg/m2on days 1, 8, and 15. The treatments were repeated every 3 weeks for six cycles. The study had 0.8 power to detect 5 months increase in median PFS at 0.05 two-sided alpha. Results: Of 637patients who underwent randomization, 631were eligible. After median follow-up of 29 m PFS in the c-TC group and dd-TC group overall survival at 2 years was 77.7% and 83.6%, respectively (P=0.05). Isonishi et al ASCO 2008 was 17.1 and 27.9m , (P=0.0014)

  33. IP Therapy Weekly paclitaxel Paclitaxel Cisplatin Aggressive Surgery Combination Chemotherapy Survival (mo) Paclitaxel/Carboplatin Ovarian CancerSurvival after Treatment

  34. Copy Number Analysis by Platinum Sensitive (Blue) and Resistant (Red) Ovarian Cancer Cases n=89 serous tumours Etemadmoghadam et al Clin Can Res 2009

  35. Ovarian Surface Epithelium

More Related